Hims & Hers Health (NYSE:HIMS) Stock Price Up 2.9% – Here’s What Happened

Hims & Hers Health, Inc. (NYSE:HIMS) shares traded up 2.9% during trading on Monday . The company traded as high as $34.70 and last traded at $34.10. 5,594,673 shares were traded during trading, a decline of 59% from the average session volume of 13,489,024 shares. The stock had previously closed at $33.14.

Analysts Set New Price Targets

A number of brokerages recently issued reports on HIMS. Leerink Partners increased their price objective on Hims & Hers Health from $24.00 to $40.00 and gave the stock a “market perform” rating in a research report on Tuesday, February 25th. Citigroup reiterated a “sell” rating and set a $27.00 price target on shares of Hims & Hers Health in a research report on Thursday, March 6th. Bank of America reiterated an “underperform” rating and set a $21.00 target price on shares of Hims & Hers Health in a research report on Thursday, March 6th. Canaccord Genuity Group increased their price target on shares of Hims & Hers Health from $38.00 to $68.00 and gave the stock a “buy” rating in a report on Wednesday, February 19th. Finally, BTIG Research initiated coverage on shares of Hims & Hers Health in a research report on Tuesday, January 7th. They issued a “buy” rating and a $35.00 target price for the company. Two analysts have rated the stock with a sell rating, seven have given a hold rating and six have issued a buy rating to the company. Based on data from MarketBeat.com, Hims & Hers Health currently has an average rating of “Hold” and an average target price of $37.23.

Hims & Hers Health Price Performance

The firm has a market cap of $7.85 billion, a PE ratio of 80.34 and a beta of 1.37. The stock has a 50 day simple moving average of $38.49 and a 200-day simple moving average of $28.23.

Hims & Hers Health (NYSE:HIMS) last posted its earnings results on Monday, February 24th. The company reported $0.11 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.09 by $0.02. The business had revenue of $481.14 million for the quarter, compared to analysts’ expectations of $494.56 million. Hims & Hers Health had a net margin of 8.19% and a return on equity of 10.97%. As a group, equities analysts predict that Hims & Hers Health, Inc. will post 0.29 EPS for the current fiscal year.

Insider Buying and Selling at Hims & Hers Health

In other Hims & Hers Health news, insider Michael Chi sold 7,500 shares of the company’s stock in a transaction on Thursday, December 19th. The shares were sold at an average price of $26.00, for a total value of $195,000.00. Following the sale, the insider now directly owns 193,601 shares of the company’s stock, valued at approximately $5,033,626. This represents a 3.73 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Soleil Boughton sold 268,932 shares of the business’s stock in a transaction that occurred on Monday, January 6th. The shares were sold at an average price of $27.75, for a total value of $7,462,863.00. Following the completion of the transaction, the insider now directly owns 169,803 shares of the company’s stock, valued at $4,712,033.25. The trade was a 61.30 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 890,592 shares of company stock valued at $31,677,291 in the last three months. Company insiders own 17.71% of the company’s stock.

Institutional Trading of Hims & Hers Health

Several institutional investors have recently bought and sold shares of HIMS. Crewe Advisors LLC acquired a new position in Hims & Hers Health during the fourth quarter worth about $28,000. Raleigh Capital Management Inc. grew its holdings in shares of Hims & Hers Health by 1,100.0% in the fourth quarter. Raleigh Capital Management Inc. now owns 1,200 shares of the company’s stock valued at $29,000 after purchasing an additional 1,100 shares during the period. Blume Capital Management Inc. increased its position in Hims & Hers Health by 100.0% during the fourth quarter. Blume Capital Management Inc. now owns 1,200 shares of the company’s stock worth $29,000 after purchasing an additional 600 shares during the last quarter. Smartleaf Asset Management LLC increased its holdings in shares of Hims & Hers Health by 4,415.6% during the 4th quarter. Smartleaf Asset Management LLC now owns 1,445 shares of the company’s stock worth $36,000 after buying an additional 1,413 shares during the last quarter. Finally, Summit Securities Group LLC acquired a new position in shares of Hims & Hers Health in the 4th quarter valued at $38,000. 63.52% of the stock is owned by institutional investors and hedge funds.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.